Document Type
Poster
Publication Date
12-2012
Abstract
Presented at ACC Mid-Atlantic conference in Washington DC.
INTRODUCTION/HYPOTHESIS
•Adverse cardiac remodeling and fibrosis provide an arrhythmic substrate for atrial fibrillation (AF), but the role of matrix metalloproteinases (MMPs) as a biomarker is not well understood. MMPs are zinc-dependent endopeptidases known to degrade substrates such as elastin, gelatin and collagen.
•In excised human atrial tissue, MMP 2 and 9 levels rise as the AF burden increases from sinus rhythm (“No AF”) to non-permanent AF (“Non-Prm AF”) to permanent AF (“PrmAF”). Higher plasma levels of MMPs are also associated with recurrent AF after cardioversion.
•This study sought to elucidate 1) the relationship of these biomarker levels with AF burden and 2) the predictive value of biomarkers for future AF episode in patients with severely reduced left ventricular ejection fraction (LVEF) and implantable cardioverter-defibrillators (ICDs)
Recommended Citation
Okabe, MD, Toshimasa; Chandra, Avinash; Natan, Shaw R.; Adams, Suzanne; Sendecki, Jocelyn A.; McCarey, Melissa M.; Ho, MD, Reginald; Pavri, MD, Behzad B.; Greenspon, MD, Arnold J.; and Frisch, MD, Daniel, "Matrix Metalloproteinase Levels Identify Heart Failure Patients with Higher Burden of Atrial Fibrillation" (2012). Department of Medicine Faculty Papers. Paper 84.
https://jdc.jefferson.edu/medfp/84
